Empirical Financial Services LLC d.b.a. Empirical Wealth Management Raises Position in Novo Nordisk A/S (NYSE:NVO)

Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 8.4% during the fourth quarter, HoldingsChannel reports. The firm owned 7,453 shares of the company’s stock after purchasing an additional 578 shares during the quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Novo Nordisk A/S were worth $641,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in NVO. Stablepoint Partners LLC raised its position in shares of Novo Nordisk A/S by 5.2% in the 4th quarter. Stablepoint Partners LLC now owns 12,068 shares of the company’s stock worth $1,038,000 after buying an additional 600 shares during the period. Novare Capital Management LLC raised its position in shares of Novo Nordisk A/S by 25.6% in the 4th quarter. Novare Capital Management LLC now owns 3,424 shares of the company’s stock worth $295,000 after buying an additional 697 shares during the period. Embree Financial Group purchased a new position in shares of Novo Nordisk A/S in the 4th quarter worth $1,210,000. KFG Wealth Management LLC raised its position in shares of Novo Nordisk A/S by 14.9% in the 4th quarter. KFG Wealth Management LLC now owns 4,821 shares of the company’s stock worth $415,000 after buying an additional 626 shares during the period. Finally, Asio Capital LLC raised its position in shares of Novo Nordisk A/S by 5.3% in the 4th quarter. Asio Capital LLC now owns 5,301 shares of the company’s stock worth $456,000 after buying an additional 266 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 2.9 %

Shares of Novo Nordisk A/S stock opened at $85.00 on Wednesday. The business has a 50-day moving average of $95.10 and a 200-day moving average of $114.43. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company has a market capitalization of $381.45 billion, a PE ratio of 27.51, a P/E/G ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on NVO. BMO Capital Markets cut their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.